Chief Executive Officer, sunshineHeart
Stories naming Don Rohrbaugh. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sunshine Heart announces that two female patients at Louisville's Jewish Hospital are the first US women implanted with its C-Pulse heart assist system in an FDA-approved 20-patient feasibility trial.
Medical device maker Sunshine Heart reports its first two American C-Pulse patients cleared three-month follow-ups, booked initial reimbursement revenue from an Ohio trial site, and outlines coming CE Mark and FDA steps.
Sunshine Heart's board will weigh ways to secure extra funding after starting its US heart device trial; finance chief Brian Bolton retires, with Rowena Hubble becoming company secretary.
Sunshine Heart reports the first two US implants of its C-Pulse heart assist device, performed at Ohio State under a 20-patient FDA-approved feasibility trial running across six American hospitals.
Sunshine Heart says a Kentucky hospital is the first US site cleared by an ethics board to join its FDA-approved C-Pulse heart failure trial, with patient enrolment expected once contracts are signed.
Sunshine Heart won complete US regulator clearance to run its first American trial of the C-Pulse heart device, having satisfied conditions attached to September's conditional clearance; enrolment of trial participants was anticipated that year.
Sunshine Heart has eliminated its chief operating officer role, with Victor Windeyer departing as the company restructures its St Leonards operation; chief technical officer Dr William Peters resumes managing development.
Board change at Sunshine Heart: Nicholas Callinan takes the chairman role at the October 2008 annual meeting as Malcolm McComas steps down from it but stays a director; Callinan's venture capital career is profiled.
Sunshine Heart's Sydney subsidiary has named Victor Windeyer general manager while he remains chief operating officer of the American-listed parent, overseeing Australian operations ahead of a planned United States clinical trial filing.
Sunshine Heart's CEO showcased its C-Pulse cardiac support technology at a US bioventures conference; backer CM Capital attended, and the medtech firm readied US feasibility trials for its second-generation system.
Sunshine Heart, an ASX-listed medical device company, appoints Brian Bolton as its chief financial officer and company secretary from April 2007, thanking interim CFO Steven Skinner, ahead of United States clinical trials.
Device maker Sunshine Heart said its C-Pulse product moved closer to human trials in America after a positive regulator meeting, with a formal application planned for mid-2007 and hospitals already lined up.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures